Niosome minoxidil

PreclinicalSmall molecule

AAssiut University

Niosome minoxidil is one of 39 small molecule programs targeting Alopecia Areata. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alopecia AreataActive, not recruiting

Alopecia AreataPreclinical

Active, not recruiting

Competition

Competitive Landscape

113 competitors in Alopecia Areata

#DrugCompanyPhaseTrials

Olumiant

Eli Lilly

Phase 3

5 2

Opzelura

Pfizer

Phase 3

5 3

Rinvoq

AbbVie

Phase 3

2 4

PF-06651600

Pfizer

Phase 3

4 5

Orencia

Bristol-Myers Squibb

Phase 2

2 6

Jaktinib

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3

4 7

Cosentyx

Novartis

Phase 2

1 8

Jakafi

Incyte

Phase 2

1 9

SHR0302

RReistone Biopharma Company Limited

Phase 3

2 10

IL2

AAssistance Publique - Hôpitaux de Paris

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alopecia Areata1 trial

Role of Minoxidil in Alopecia Areata Transepidermal Drug Delivery of Minoxidil Via Either Fractional Carbon Dioxide Laser or Microneedling Versus Its Topical Nanoparticles Preparation for Treatment of Alopecia Areata

Unknown status·—·N/A·NCT05587257·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Niosome minoxidil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Niosome minoxidil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Niosome minoxidil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assiut University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAssiut University

Niosome minoxidil

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alopecia Areata1 trial

References

Drug Info

Quick Facts

Related News